Search results
Results From The WOW.Com Content Network
Dual-energy X-ray absorptiometry (DXA, or DEXA [1]) is a means of measuring bone mineral density (BMD) with spectral imaging. Two X-ray beams, with different energy levels, are aimed at the patient's bones. When soft tissue absorption is subtracted, the bone mineral density (BMD) can be determined from the absorption of each beam by bone. Dual ...
A scanner used to measure bone density using dual energy X-ray absorptiometry. Bone density, or bone mineral density, is the amount of bone mineral in bone tissue.The concept is of mass of mineral per volume of bone (relating to density in the physics sense), although clinically it is measured by proxy according to optical density per square centimetre of bone surface upon imaging. [1]
Osteopenia, known as "low bone mass" or "low bone density", is a condition in which bone mineral density is low. [1] Because their bones are weaker, people with osteopenia may have a higher risk of fractures, and some people may go on to develop osteoporosis. [2]
bone density studies for osteoporosis assessment Dual X-ray absorptiometry and laser technique (DXL) in the area of bone density studies for osteoporosis assessment is an improvement to the DXA Technique , adding an exact laser measurement of the thickness of the region scanned.
A wide variety of body composition measurement methods exist. The gold standard measurement technique for the 4-compartment model consists of a weight measurement, body density measurement using hydrostatic weighing or air displacement plethysmography, total body water calculation using isotope dilution analysis, and mineral content measurement by dual-energy X-ray absorptiometry (DEXA). [1]
About 22 million women and 5.5 million men in the European Union had osteoporosis in 2010. [15] In the United States in 2010, about 8 million women and between 1 and 2 million men had osteoporosis. [13] [16] White and Asian people are at greater risk. [3] The word "osteoporosis" is from the Greek terms for "porous bones". [17]
In 2018, HHS released an update to the first set of guidelines. This 2018 edition provides guidelines for people aged three years and older and summarizes the new knowledge gained from studies that were conducted since the first edition was released in 2008. These Guidelines can be tailored to meet individual interests, lifestyles, and goals.
The International Osteoporosis Foundation and the European Calcified Tissue Society recommend pharmacological therapy for osteoporosis in postmenopausal women and men ≥70 years, with a previous fragility fracture, or a dose equivalent of prednisone ≥7.5 mg daily for ≥3 months. For premenopausal women and men <50 years taking steroids for ...